ZIOPHARM Oncology Inc stock performance trend indicates that the stock price has rallied 7.81% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 12.79% . Looking at the past 52 week period, the stock price is down -17.1% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of ZIOPHARM Oncology Inc has a negative value of -24.68 compared to overall market performance.ZIOPHARM Oncology, Inc. is having a Relative Strength Index of 49.16 which indicates the stock is not yet over sold or over bought based on the technical indicators.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has tumbled 7.84% during the past week and has dropped 7.43% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.06%. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has underperformed the index by 8.49% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company shares have received an average consensus rating of Hold for the current week ZIOPHARM Oncology Inc (NASDAQ:ZIOP) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.14 points or 2.16% at $6.35 with 1,452,524 shares getting traded. Post opening the session at $6.35, the shares hit an intraday low of $6.31 and an intraday high of $6.54 and the price was in this range throughout the day. The company has a market cap of $841 million and the number of outstanding shares has been calculated to be 132,376,670 shares. The 52-week high of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is $9.19 and the 52-week low is $4.45.
Company has reported several Insider transactions to the SEC, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at 12.84 per share price.On Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at 10.12 per share price.On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at 9.67 per share price.
ZIOPHARM Oncology Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.11 EPS for the quarter. Analyst had a consensus estimate of $-0.11. The company had revenue of $1.60 million for the quarter, compared to analysts expectations of $1.45 million. The companys revenue was down -15.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.14 EPS.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.